MedTrace Logo

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-09-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

memantine

Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT

DRUG

Placebo Oral Capsule

Patients received a placebo capsule starting the day before ECT begins and while receiving ECT

Sponsors & Collaborators

Principal Investigators

  • Hugh Brent Solvason · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2006-02-28
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186498 on ClinicalTrials.gov